论文部分内容阅读
目的探讨匹多莫德联合阿维A胶囊治疗复发性尖锐湿疣(CA)人乳头瘤病毒(HPV)亚型的应用价值。方法以随机数字表法将66例复发性CA HPV亚型患者分为两组,每组33例。以接受二氧化碳激光治疗者为对照组,以在接受二氧化碳激光治疗同时联合应用匹多莫德及阿维A胶囊治疗者为观察组。对比两组治疗前后T淋巴细胞亚群变化情况及临床治疗效果。结果两组间入组时DLQI评分、SCL-90评分、CD_3~+、CD_4~+、CD8+百分比及CD_4~+/CD8+比较差异未见统计学意义(P>0.05);而在接受治疗3个月后,观察组DLQI评分及CD8+百分比低于对照组,SCL-90评分、CD_3~+、CD_4~+百分比及CD_4~+/CD8+高于对照组(P<0.05)。观察组治疗总有效率明显高于对照组(P<0.05)。观察组治疗不良反应发生率明显低于对照组(P<0.05)。结论匹多莫德联合阿维A胶囊治疗可有效改善复发性CA HPV亚型免疫指标,并可在有效的提高治疗效果的同时,显著的降低不良反应发生率。
Objective To investigate the application of pidotimod in combination with Avia A capsule in the treatment of human papillomavirus (HPV) subtype of recurrent condyloma acuminatum (CA). Methods Sixty-six patients with recurrent CA HPV subtype were divided into two groups (n = 33 in each group) by random number table. To accept carbon dioxide laser treatment for the control group, to receive carbon dioxide laser treatment combined with pidmodoed and Avia A capsule treatment for the observation group. The changes of T lymphocyte subsets and the clinical effect of the two groups before and after treatment were compared. Results There was no significant difference in DLQI score, SCL-90 score, percentage of CD_3 ~ +, CD_4 ~ +, CD8 + and CD_4 ~ + / CD8 between the two groups (P> 0.05) Months later, the DLQI score and percentage of CD8 + in the observation group were lower than those in the control group. SCL-90 score, percentage of CD_3 ~ +, CD_4 ~ + and CD_4 ~ + / CD8 + were higher in the observation group than those in the control group (P <0.05). The total effective rate of observation group was significantly higher than that of control group (P <0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P <0.05). Conclusion Pidotimod combined with Avia A capsule can effectively improve the recurrence of CA HPV subtype immune indicators, and can effectively improve the treatment effect, significantly reduce the incidence of adverse reactions.